Literature DB >> 34199771

Smoking from a Younger Age Is the Dominant Factor in the Incidence of Chronic Obstructive Pulmonary Disease: Case-Control Study.

Winda Safitri1, Santi Martini2, Kurnia Dwi Artanti2,3, Chung-Yi Li4,5,6.   

Abstract

BACKGROUND: Indonesia ranks 7th highest in the world for the number of deaths caused by tobacco use including those caused by Chronic Obstructive Pulmonary Disease (COPD). The purpose of this study was to determine the influence of initial smoking age and habit on the incidence of COPD.
METHODS: This research was a case-control study. The sampling in this research took a systematic random sampling method. The samples of this study were 56 respondents of a case group and 56 respondents of a control group. This study was conducted at Ngudi Waluyo Hospital, Wlingi, Blitar from October to November 2017.
RESULTS: The factors that influenced the incidence of COPD were being male (p = 0.00; OR = 6.333; 95%CI = 2.776-14.450), a smoker (p = 0.00050; OR = 5.1318; 95%CI = 1.9004-13.8958), initially smoking at <15 years old (p = 0.00; OR = 11,769; 95%CI = 4.086-33.903), initially getting into a smoking habit at the age of <15 years old (OR = 12; CI = 1346-106,950), initially getting into a smoking habit at the age of ≥15 years old (OR = 3647; CI = 1625-8183) and having smoked for ≥30 years (OR = 8857; CI = 3298-23,787).
CONCLUSION: There are three factors of smoking behavior that influence COPD: smoking habit, initial smoking age and smoking duration. Of all factors, forming a smoking habit at the age of <15 years old has the biggest risk (OR = 12; CI = 1346-106,950).

Entities:  

Keywords:  chronic obstructive pulmonary disease; initial smoking age; smoking duration; smoking habit; tobacco use

Mesh:

Year:  2021        PMID: 34199771      PMCID: PMC8200000          DOI: 10.3390/ijerph18116047

Source DB:  PubMed          Journal:  Int J Environ Res Public Health        ISSN: 1660-4601            Impact factor:   3.390


1. Introduction

Chronic obstructive pulmonary disease (COPD) is a non-communicable disease with an incidence worldwide that increases from year to year [1]. COPD is a major source of morbidity, mortality and cost in the Western world [2]. Currently, the number of people with COPD globally reaches 384 million; it is estimated that this number will continue to increase, with COPD becoming the third-leading cause of death in the world by 2030 [3]. The burden of chronic respiratory diseases is generally increasing across the globe, and COPD is one of the main causes of mortality and morbidity [2]. The main risk factor for COPD is smoking [3]. Cigarette smoking has been shown to be the leading cause of COPD in the United States [4]. The pathogenesis of smoking-related COPD includes the protease, anti-protease and oxidant-antioxidant hypotheses and abnormal repair processes [5]. COPD caused by smoking is usually initiated by injury to the lungs. A smoking habit is the cause of eight out of ten cases of COPD [6]. More than 75% of COPD cases result from lung injury caused by a long period of smoking [7]. Other risk factors that can influence COPD are environmental exposure to biomass fuels and air pollution, and host factors such as age, sex or socioeconomic status [3,8]. Age is often listed as a risk factor for COPD as all vital organs lose their function with age, hence the decline in lung function, which occurs progressively after about 25 years of age. In the case of COPD, the age factor plays a role in increased cell aging, stem cell fatigue, increased oxidative stress, changes in the extracellular matrix and a reduction in endogenous anti-aging molecules and protective pathways such as autophagy [9]. In the past, most studies have shown that the prevalence and mortality of COPD are higher in men than women, but recent studies in developed countries have reported that the prevalence of COPD in men and women is almost the same. This may be due to changes in smoking behavior patterns [10]. COPD is the first cause of disability in the world [11]. Limited ability to perform daily activities occurs in three out of four cases of COPD [12]. The disease also limits a person’s ability to climb the stairs [13]. Early retirement occurs in 40% of patients with COPD [14]. In Europe, COPD accounts for 50% of total health funds each year and causes an annual productivity loss of €48.4 billion [15]. In the United States, it is estimated that COPD costs $50 billion each year, consisting of direct costs of as much as $30 billion and further indirect costs reaching $20 billion [16]. It is estimated that 12 million people suffer from COPD and that 120,000 die of the condition each year [17]. In Indonesia, COPD results in a total daily loss of productivity of 901,744 h and medical expenses of IDR 1,294,165,188,810; it is the sixth-leading cause of death nationally [18]. As such, it is necessary to make a preventive effort to reduce the prevalence of COPD. With that aim in mind, the purpose of this study is to determine the influence of initial smoking age and habit on the incidence of COPD. Health is a human right mandated by the 1945 Constitution of the Republic of Indonesia; therefore, there is a need tobacco control for protection against the effects of cigarette smoke, especially for people who are not active smokers, in accordance with Health Law No. 36 of 2009 article 115 concerning the establishment of a No Smoking Zone (KTR) policy as part of government efforts to protect the public in the public environment. Based on 2013 health data, out of 38 districts/cities, only nine had implemented the KTR policy in East Java Province [19]. Blitar, a district in East Java, had still not implemented this regulation in 2018, despite one of the diseases caused by smoking, namely COPD, having a fairly high prevalence (3.7%) in the district compared to other diseases [19]. Based on a recapitulation of patient data from Ngudi Waluyo Wlingi Hospital, Blitar District, in 2016, the morbidity rate of COPD inpatients was ranked tenth with 226 patients, while for outpatient care, COPD was ranked thirteenth with 953 patients [18]. The main risk factor for COPD is exposure to cigarette smoke. Of the total population aged ≥10 years in Blitar District, 36.3% have a history of smoking habits, with 30% still actively smoking. In Blitar District, the average number of cigarettes smoked per person per day in 2013 was 9.7 cigarettes [19].

2. Material and Methods

2.1. Study Area

This study took place in Ngudi Waluyo Wlingi Hospital, Blitar District, Indonesia. Worldwide, Indonesia has the 7th highest number of deaths due to COPD, while Blitar district is one of the districts in East Java, Indonesia that does not have regulations regarding smoking-free areas. As a result, the prevalence of smoking-related diseases is high in Blitar District, one of which is COPD. The prevalence of COPD in Blitar District, East Java, Indonesia is 3.7% [19]. Ngudi Waluyo Wlingi Regional Hospital was designated as a Regional Public Service Agency (BLUD) Hospital in Blitar. It is a teaching hospital that has 16 accredited services and, as such, a suitable place for research. Based on a recapitulation of patient data from Ngudi Waluyo Wlingi Hospital, Blitar District, in 2016, the morbidity rate of inpatient COPD was ranked tenth with 226 patients, while for outpatient care, COPD was ranked thirteenth with 953 people [20].

2.2. Data Source

This research was an analytical observational study using a case-control design. This research was conducted in April–December 2017 at Ngudi Waluyo Hospital in Wlingi, Blitar, East Java, Indonesia. The case group was people who had been diagnosed as suffering from COPD, while the control group was people who had never been diagnosed as suffering from COPD.

2.3. Sample Selection

The sampling used in this study was systematic random sampling. The case population in this study was patients with COPD aged ≥30 years at Ngudi Waluyo Wlingi Regional Hospital, Blitar District, East Java. The diagnosis of COPD was determined based on the doctor’s diagnosis on the patient’s medical record. Meanwhile, the control population in this study were all patients aged ≥30 years who did not have a history of COPD based on medical records from Ngudi Waluyo Wlingi Regional Hospital, Blitar District, East Java. The sample size was calculated using Lemeshow’s comparison case, which generated 56 samples in each group (1:1). The samples were divided into case and control groups. The case group consisted of samples with COPD, while the control group consisted of samples without COPD. The cases and controls were selected randomly using a systematic random sampling technique. The control group was selected based on the current age of the respondent, namely, at least 30 years old. Systematic random sampling was carried out in both the case and control groups based on the serial numbers of patients seeking treatment at Ngudi Waluyo Hospital. This was based on the number of patients receiving treatment divided by the number of samples needed; the sample was taken based on the multiple of the results of the distribution in the sampling frame.

2.4. The Operational Definition of the Variable

The dependent variable studied was COPD, while the independent variables studied were divided into two groups: characteristics of respondents (age, sex, job and education) and smoking behavior (smoking habits, early smoking age and duration of smoking). Determination of COPD status was made in the case group using medical records and in the control group using a questionnaire. The age variable was determined based on the interview date and the respondent’s date of birth, and grouped into two categories: adult (≥30–<65 years old) and elderly (≥65 years old). The sex variable was divided into two categories: male and female. The education variable was divided into two categories: low education (from no school up to junior high school) and higher education (from senior high school to college). The smoking habit variable was divided into three variables: non-smokers (never smoked), smokers (people who have smoked at least 100 cigarettes in their lifetime but in the environments where they live and work there are no smokers) and smokers who were exposed to secondhand smoke (smokers who are exposed to cigarette smoke itself and from other people). The variable of initial smoking age was divided into three groups: non-smokers, smokers who initially smoked at <15 years old and smokers who initially smoked at ≥15 years old. The variable of smoking duration was divided into three groups: non-smokers, smokers who smoked for <30 years and smokers who smoked for ≥30 years.

2.5. Instruments

Data collection was carried out using a questionnaire and secondary data, i.e., patient medical records. The questionnaire used in this study was a modification of that for basic health research and non-communicable disease research. The questionnaire was on participants’ smoking habits and statuses in relation to COPD. The questionnaire had been tested on 20 respondents to ensure its validity and reliability.

2.6. Statistical Analysis

The collected data were then analyzed descriptively and analytically with computer assistance. Data processing was carried out with bivariate analysis using the confidence of interval of 95% (α = 0.05).

2.7. Ethical Clearance

All participants were provided with written informed consent approved by the Ethics Commission of the Faculty of Public Health, Universitas Airlangga (certificate number: 536-KEPK).

3. Results

3.1. Characteristics of Respondents

Table 1 presents the distribution of respondent characteristics and their effects on the incidence of COPD, showing that of a total of 112 respondents, the majority of the COPD patients were male (75%), elderly (53.57%) and had a low educational background (67.86%). Significant results showed that males had a 6.33 times greater risk than females (p = 0.00; OR = 6.333; 95%CI = 2.776–14.450) and that the elderly group had an 11.769 times greater risk than respondents in the adult group (p = 0.00; OR = 11,769; 95%CI = 4.086–33.903).
Table 1

Characteristics of Respondents.

VariablesCaseControl p OR95% CI
n%n%
Sex
Male4275.001832.140.006.3332.776–14.450
Female1425.003867.86
Age
Elderly (≥65 years old)3053.5758.930.0011.7694.086–33.903
Adult (≥30–<65 years old)2646.435191.07
Education
Low Education3867.863664.290.691.1730.536–2.567
High Education1832.142035.7
Total56100.0056100.00

3.2. Smoking Behavior

Table 2 presents the distribution of respondents’ smoking behavior and its effect on the incidence of COPD, showing that of a total of 112 respondents, 55 were smokers and 57 were non-smokers, with 29 of the latter exposed to secondhand smoke.
Table 2

Smoking Behavior of Respondents.

VariablesCaseControl p OR95% CI
n%n%
Smoking Habit
Non-Smokers814.282035.72
Secondhand Smokers1119.641832.140.2361.52780.5028–4.6418
Smokers 3766.071832.140.000505.13181.9004–13.8958
Initial Smoking Age
Non-Smokers1933.933867.86 2.599–13.620
Smokers who initially smoked at <15 years old610.711.790.026121.346–106.95
Smokers who initially smoked at ≥15 years old3155.41730.350.0023.6471.625–8.183
Smoking Duration
Non-Smokers1933.933867.86
Smokers who smoked for <30 years610.711119.640.8811.0910.350–3.401
Smokers who smoked for ≥30 years3155.36712.50.0008.8573.298–23.787
Total56100.0056100.00
Significant results showed that smokers had a 5.1318 times greater risk of developing COPD compared with non-smokers (p = 0.00050; OR = 5.1318; 95%CI = 1.9004–13.8958). Yet, secondhand smokers had no influence on the incidence of COPD (p = 0.236; OR = 1.5278; 95%CI = 0.5028–4.6418). Significant results also showed that smokers who initially smoked at <15 years old had a 12 times greater risk of developing COPD compared with non-smokers (p = 0.026; OR = 12; 95%CI = 1.346–106.95), while smokers who initially smoked at ≥ 15 years old had a 3.647 times greater risk of developing COPD than non-smokers (p = 0.002; OR = 3.647; 95%CI = 3.298–23.787). A smoking period of fewer than 30 years did not influence the incidence of COPD (p = 0.881; OR = 1.091; 95%CI = 0.350–3.401), while a smoking period of more than 30 years was influential. Smokers who smoked for more than 30 years had an 8.857 times greater risk of developing COPD compared with non-smokers (p = 0.000; OR = 8.857; 95%CI = 3.298–23.787) (Table 2).

4. Discussion

4.1. Key Findings

The factors that influenced the incidence of COPD were being male (p = 0.00; OR = 6.333; 95%CI = 2.776–14.450), elderly (p = 0.00; OR = 11,769; 95%CI = 4.086–33.903), a smoker (p = 0.00050; OR = 5.1318; 95%CI = 1.9004–13.8958), developing an initial smoking habit at the age of <15 years old (p = 0.026; OR = 12; 95%CI = 1.346–106.95), developing an initial smoking habit at the age of ≥15 years old (OR = 3647; 95%CI = 1625–8183) and smoking for ≥30 years (OR = 8857; 95%CI = 3298–23,787).

4.2. Characteristics of Respondents

The current study showed that the OR value of the elderly group was higher than that of the adult group (p = 0.00; OR = 11,769; 95%CI = 4.086–33.903). This is in line with previous studies in Sousse, Tunisia in 2013 on elderly patients >70 years (p = 0.007; OR = 10,403; 95% CI = 2072–52,222) and in west and northern Sweden over 2008–2012 on elderly patients ≥60 years (OR = 8.40; 95%CI = 3.70–19.1), as well as based on the results of Indonesian health data from 2013 for elderly patients ≥60 years (OR = 4.5; 95%CI = 7.6–8.2) [21,22,23]. The three previous research studies have similar results, namely, that the elderly group has the highest risk of suffering from COPD versus other age groups. The current study showed that the OR value of the male group was higher than for the female group (p = 0.013; OR = 3.273; 95%CI = 1.291–8.2999). This is in line with previous studies in Sousse, Tunisia in 2013 on a male group (p = 0.010; OR = 0.198 95%CI = 0.062–0.635) and in Anhui, China on a male group (OR = 2.01; 95%CI = 1.22–3.33), along with Indonesian health data from 2013 for a male group (OR = 1.3; 95%CI = 4–4.3) [21,22,24,25]. The four previous research studies have similar results, namely, that males have a higher risk of suffering from COPD than females. The differences in the ORs in each study, both for age and sex, could be caused by several factors, such as differences in the methods used and numbers of samples taken, and bias resulting from other influential risk factors.

4.3. Smoking Behavior

4.3.1. Smoking Habit

The current study shows that the OR values for smokers are higher than those for other groups (p = 0.00050; OR = 5.1318; 95%CI = 1.9004–13.8958). This is in line with a previous study in 2019 in the Abeshge District, Southern Ethiopia on a smokers group (OR = 4.19; 95%CI = 2.59–6.78) [8]. Two previous studies in Sousse, Tunisia and Anhui, China, which described the smoking group in more detail, showed that current smokers have a higher risk than former smokers [21,25]. When compared with three previous studies, the OR value of a smoking habit in this study was higher than in those before. This may be because the methods used in this study were different and the number of participants was smaller. However, there was a similarity in that the smoker group had a greater risk of suffering from COPD than the non-smoker group. Smoking cigarettes over a long period disrupts ciliary movement, inhibits alveolar macrophage function and ultimately, leads to hypertrophy and hyperplasia of the mucus excreting gland [26]. Cigarette smoke contains many species of reactive oxygen (free radicals), which deplete the antioxidant mechanism, resulting in tissue damage and potentially leading to COPD [27].

4.3.2. Initial Smoking Age

Developing a smoking habit at the age of <15 years old presents the biggest risk, more so than any other (OR = 12; 95%CI = 1346–106,950). There is a significantly higher risk of COPD when starting smoking at <15 years of age (3.647–12%) than ≥15 years old as smoking in childhood and adolescence can slow the growth and development of the lungs, thereby increasing the risk of incidence of COPD during adulthood. The lungs still grow and develop until the age of 20 years; therefore, smoking prior to the age of 20 years causes one’s lungs to develop sub-optimally both in terms of ability and function. These kinds of lungs fail to work properly, produce breath that tends to be short and will cause problems when used to exercise or perform physical activity. Although the health of people who quit smoking will increase dramatically compared with their health when they smoked, some cases of lung damage at an early age due to cigarettes are irreversible [28]. Therefore, it is necessary to implement policies regarding age restrictions on the purchase of cigarettes, especially for mobile cigarette sellers, as well as fostering cross-sector cooperation between health, education and other government sectors to spread the message about the dangers of smoking from an early age.

4.3.3. Smoking Duration

Smokers who smoked for more than 30 years had an 8.857 times greater risk of developing COPD compared with non-smokers (p = 0.000; OR = 8.857; 95%CI = 3.298–23.787). Yet, the results for smoking <30 years were not in line with other studies, which showed that smoking has an effect, i.e., that someone who has had a smoking habit for >20 years is three to four times more likely to develop COPD compared to someone whose has had a smoking habit for ≤20 years [29]. The result of this study may have been influenced by exposure to cigarette smoke from other people, as of the 55 respondents who smoked, 26 were also exposed to cigarette smoke from other people, which could have disturbed the results of the study. Nonetheless, the results for smoking ≥30 years are in line with other literature stating that the longer the smoking habit, the greater the risk of developing COPD [30].

5. Conclusions

A starting age for smoking of less than 15 years old has the highest risk (OR = 12; 95%CI = 1346–106,950) for COPD. The other factors that influenced the incidence of COPD were being male (p = 0.00; OR = 6.333; 95%CI = 2.776–14.450), elderly (p = 0.00; OR = 11,769; 95%CI = 4.086–33.903) and with a smoking duration ≥ 30 years (OR = 8857; 95%CI = 3298–23,787).
  14 in total

1.  Prevalence and risk factors of COPD among never-smokers in two areas of Sweden - Occupational exposure to gas, dust or fumes is an important risk factor.

Authors:  Stig Hagstad; Helena Backman; Anders Bjerg; Linda Ekerljung; Xiong Ye; Linnea Hedman; Anne Lindberg; Kjell Torén; Jan Lötvall; Eva Rönmark; Bo Lundbäck
Journal:  Respir Med       Date:  2015-09-26       Impact factor: 3.415

Review 2.  The global economic burden of asthma and chronic obstructive pulmonary disease.

Authors:  S Ehteshami-Afshar; J M FitzGerald; M M Doyle-Waters; M Sadatsafavi
Journal:  Int J Tuberc Lung Dis       Date:  2016-01       Impact factor: 2.373

Review 3.  Burden of chronic obstructive pulmonary disease: healthcare costs and beyond.

Authors:  Sara M May; James T C Li
Journal:  Allergy Asthma Proc       Date:  2015 Jan-Feb       Impact factor: 2.587

4.  Health-related quality of life in patients by COPD severity within primary care in Europe.

Authors:  P W Jones; G Brusselle; R W Dal Negro; M Ferrer; P Kardos; M L Levy; T Perez; J J Soler-Cataluña; T van der Molen; L Adamek; N Banik
Journal:  Respir Med       Date:  2010-10-06       Impact factor: 3.415

Review 5.  Diagnosis and early detection of COPD using spirometry.

Authors:  David P Johns; Julia A E Walters; E Haydn Walters
Journal:  J Thorac Dis       Date:  2014-11       Impact factor: 2.895

Review 6.  The burden of chronic obstructive pulmonary disease.

Authors:  P Vermeire
Journal:  Respir Med       Date:  2002-08       Impact factor: 3.415

7.  Prevalence of COPD and tobacco smoking in Tunisia--results from the BOLD study.

Authors:  Hager Daldoul; Meriam Denguezli; Anamika Jithoo; Louisa Gnatiuc; Sonia Buist; Peter Burney; Zouhair Tabka; Imed Harrabi
Journal:  Int J Environ Res Public Health       Date:  2013-12-17       Impact factor: 3.390

8.  Prevalence and risk factors of chronic obstructive pulmonary disease in Anhui Province, China: a population-based survey.

Authors:  Zhenqiu Zha; Ruixue Leng; Wei Xu; Heling Bao; Yeji Chen; Liwen Fang; Zhirong Liu; Dongqing Ye
Journal:  BMC Pulm Med       Date:  2019-05-29       Impact factor: 3.317

9.  Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition.

Authors:  Christopher J L Murray; Ryan M Barber; Kyle J Foreman; Ayse Abbasoglu Ozgoren; Foad Abd-Allah; Semaw F Abera; Victor Aboyans; Jerry P Abraham; Ibrahim Abubakar; Laith J Abu-Raddad; Niveen M Abu-Rmeileh; Tom Achoki; Ilana N Ackerman; Zanfina Ademi; Arsène K Adou; José C Adsuar; Ashkan Afshin; Emilie E Agardh; Sayed Saidul Alam; Deena Alasfoor; Mohammed I Albittar; Miguel A Alegretti; Zewdie A Alemu; Rafael Alfonso-Cristancho; Samia Alhabib; Raghib Ali; François Alla; Peter Allebeck; Mohammad A Almazroa; Ubai Alsharif; Elena Alvarez; Nelson Alvis-Guzman; Azmeraw T Amare; Emmanuel A Ameh; Heresh Amini; Walid Ammar; H Ross Anderson; Benjamin O Anderson; Carl Abelardo T Antonio; Palwasha Anwari; Johan Arnlöv; Valentina S Arsic Arsenijevic; Al Artaman; Rana J Asghar; Reza Assadi; Lydia S Atkins; Marco A Avila; Baffour Awuah; Victoria F Bachman; Alaa Badawi; Maria C Bahit; Kalpana Balakrishnan; Amitava Banerjee; Suzanne L Barker-Collo; Simon Barquera; Lars Barregard; Lope H Barrero; Arindam Basu; Sanjay Basu; Mohammed O Basulaiman; Justin Beardsley; Neeraj Bedi; Ettore Beghi; Tolesa Bekele; Michelle L Bell; Corina Benjet; Derrick A Bennett; Isabela M Bensenor; Habib Benzian; Eduardo Bernabé; Amelia Bertozzi-Villa; Tariku J Beyene; Neeraj Bhala; Ashish Bhalla; Zulfiqar A Bhutta; Kelly Bienhoff; Boris Bikbov; Stan Biryukov; Jed D Blore; Christopher D Blosser; Fiona M Blyth; Megan A Bohensky; Ian W Bolliger; Berrak Bora Başara; Natan M Bornstein; Dipan Bose; Soufiane Boufous; Rupert R A Bourne; Lindsay N Boyers; Michael Brainin; Carol E Brayne; Alexandra Brazinova; Nicholas J K Breitborde; Hermann Brenner; Adam D Briggs; Peter M Brooks; Jonathan C Brown; Traolach S Brugha; Rachelle Buchbinder; Geoffrey C Buckle; Christine M Budke; Anne Bulchis; Andrew G Bulloch; Ismael R Campos-Nonato; Hélène Carabin; Jonathan R Carapetis; Rosario Cárdenas; David O Carpenter; Valeria Caso; Carlos A Castañeda-Orjuela; Ruben E Castro; Ferrán Catalá-López; Fiorella Cavalleri; Alanur Çavlin; Vineet K Chadha; Jung-Chen Chang; Fiona J Charlson; Honglei Chen; Wanqing Chen; Peggy P Chiang; Odgerel Chimed-Ochir; Rajiv Chowdhury; Hanne Christensen; Costas A Christophi; Massimo Cirillo; Matthew M Coates; Luc E Coffeng; Megan S Coggeshall; Valentina Colistro; Samantha M Colquhoun; Graham S Cooke; Cyrus Cooper; Leslie T Cooper; Luis M Coppola; Monica Cortinovis; Michael H Criqui; John A Crump; Lucia Cuevas-Nasu; Hadi Danawi; Lalit Dandona; Rakhi Dandona; Emily Dansereau; Paul I Dargan; Gail Davey; Adrian Davis; Dragos V Davitoiu; Anand Dayama; Diego De Leo; Louisa Degenhardt; Borja Del Pozo-Cruz; Robert P Dellavalle; Kebede Deribe; Sarah Derrett; Don C Des Jarlais; Muluken Dessalegn; Samath D Dharmaratne; Mukesh K Dherani; Cesar Diaz-Torné; Daniel Dicker; Eric L Ding; Klara Dokova; E Ray Dorsey; Tim R Driscoll; Leilei Duan; Herbert C Duber; Beth E Ebel; Karen M Edmond; Yousef M Elshrek; Matthias Endres; Sergey P Ermakov; Holly E Erskine; Babak Eshrati; Alireza Esteghamati; Kara Estep; Emerito Jose A Faraon; Farshad Farzadfar; Derek F Fay; Valery L Feigin; David T Felson; Seyed-Mohammad Fereshtehnejad; Jefferson G Fernandes; Alize J Ferrari; Christina Fitzmaurice; Abraham D Flaxman; Thomas D Fleming; Nataliya Foigt; Mohammad H Forouzanfar; F Gerry R Fowkes; Urbano Fra Paleo; Richard C Franklin; Thomas Fürst; Belinda Gabbe; Lynne Gaffikin; Fortuné G Gankpé; Johanna M Geleijnse; Bradford D Gessner; Peter Gething; Katherine B Gibney; Maurice Giroud; Giorgia Giussani; Hector Gomez Dantes; Philimon Gona; Diego González-Medina; Richard A Gosselin; Carolyn C Gotay; Atsushi Goto; Hebe N Gouda; Nicholas Graetz; Harish C Gugnani; Rahul Gupta; Rajeev Gupta; Reyna A Gutiérrez; Juanita Haagsma; Nima Hafezi-Nejad; Holly Hagan; Yara A Halasa; Randah R Hamadeh; Hannah Hamavid; Mouhanad Hammami; Jamie Hancock; Graeme J Hankey; Gillian M Hansen; Yuantao Hao; Hilda L Harb; Josep Maria Haro; Rasmus Havmoeller; Simon I Hay; Roderick J Hay; Ileana B Heredia-Pi; Kyle R Heuton; Pouria Heydarpour; Hideki Higashi; Martha Hijar; Hans W Hoek; Howard J Hoffman; H Dean Hosgood; Mazeda Hossain; Peter J Hotez; Damian G Hoy; Mohamed Hsairi; Guoqing Hu; Cheng Huang; John J Huang; Abdullatif Husseini; Chantal Huynh; Marissa L Iannarone; Kim M Iburg; Kaire Innos; Manami Inoue; Farhad Islami; Kathryn H Jacobsen; Deborah L Jarvis; Simerjot K Jassal; Sun Ha Jee; Panniyammakal Jeemon; Paul N Jensen; Vivekanand Jha; Guohong Jiang; Ying Jiang; Jost B Jonas; Knud Juel; Haidong Kan; André Karch; Corine K Karema; Chante Karimkhani; Ganesan Karthikeyan; Nicholas J Kassebaum; Anil Kaul; Norito Kawakami; Konstantin Kazanjan; Andrew H Kemp; Andre P Kengne; Andre Keren; Yousef S Khader; Shams Eldin A Khalifa; Ejaz A Khan; Gulfaraz Khan; Young-Ho Khang; Christian Kieling; Daniel Kim; Sungroul Kim; Yunjin Kim; Yohannes Kinfu; Jonas M Kinge; Miia Kivipelto; Luke D Knibbs; Ann Kristin Knudsen; Yoshihiro Kokubo; Soewarta Kosen; Sanjay Krishnaswami; Barthelemy Kuate Defo; Burcu Kucuk Bicer; Ernst J Kuipers; Chanda Kulkarni; Veena S Kulkarni; G Anil Kumar; Hmwe H Kyu; Taavi Lai; Ratilal Lalloo; Tea Lallukka; Hilton Lam; Qing Lan; Van C Lansingh; Anders Larsson; Alicia E B Lawrynowicz; Janet L Leasher; James Leigh; Ricky Leung; Carly E Levitz; Bin Li; Yichong Li; Yongmei Li; Stephen S Lim; Maggie Lind; Steven E Lipshultz; Shiwei Liu; Yang Liu; Belinda K Lloyd; Katherine T Lofgren; Giancarlo Logroscino; Katharine J Looker; Joannie Lortet-Tieulent; Paulo A Lotufo; Rafael Lozano; Robyn M Lucas; Raimundas Lunevicius; Ronan A Lyons; Stefan Ma; Michael F Macintyre; Mark T Mackay; Marek Majdan; Reza Malekzadeh; Wagner Marcenes; David J Margolis; Christopher Margono; Melvin B Marzan; Joseph R Masci; Mohammad T Mashal; Richard Matzopoulos; Bongani M Mayosi; Tasara T Mazorodze; Neil W Mcgill; John J Mcgrath; Martin Mckee; Abigail Mclain; Peter A Meaney; Catalina Medina; Man Mohan Mehndiratta; Wubegzier Mekonnen; Yohannes A Melaku; Michele Meltzer; Ziad A Memish; George A Mensah; Atte Meretoja; Francis A Mhimbira; Renata Micha; Ted R Miller; Edward J Mills; Philip B Mitchell; Charles N Mock; Norlinah Mohamed Ibrahim; Karzan A Mohammad; Ali H Mokdad; Glen L D Mola; Lorenzo Monasta; Julio C Montañez Hernandez; Marcella Montico; Thomas J Montine; Meghan D Mooney; Ami R Moore; Maziar Moradi-Lakeh; Andrew E Moran; Rintaro Mori; Joanna Moschandreas; Wilkister N Moturi; Madeline L Moyer; Dariush Mozaffarian; William T Msemburi; Ulrich O Mueller; Mitsuru Mukaigawara; Erin C Mullany; Michele E Murdoch; Joseph Murray; Kinnari S Murthy; Mohsen Naghavi; Aliya Naheed; Kovin S Naidoo; Luigi Naldi; Devina Nand; Vinay Nangia; K M Venkat Narayan; Chakib Nejjari; Sudan P Neupane; Charles R Newton; Marie Ng; Frida N Ngalesoni; Grant Nguyen; Muhammad I Nisar; Sandra Nolte; Ole F Norheim; Rosana E Norman; Bo Norrving; Luke Nyakarahuka; In-Hwan Oh; Takayoshi Ohkubo; Summer L Ohno; Bolajoko O Olusanya; John Nelson Opio; Katrina Ortblad; Alberto Ortiz; Amanda W Pain; Jeyaraj D Pandian; Carlo Irwin A Panelo; Christina Papachristou; Eun-Kee Park; Jae-Hyun Park; Scott B Patten; George C Patton; Vinod K Paul; Boris I Pavlin; Neil Pearce; David M Pereira; Rogelio Perez-Padilla; Fernando Perez-Ruiz; Norberto Perico; Aslam Pervaiz; Konrad Pesudovs; Carrie B Peterson; Max Petzold; Michael R Phillips; Bryan K Phillips; David E Phillips; Frédéric B Piel; Dietrich Plass; Dan Poenaru; Suzanne Polinder; Daniel Pope; Svetlana Popova; Richie G Poulton; Farshad Pourmalek; Dorairaj Prabhakaran; Noela M Prasad; Rachel L Pullan; Dima M Qato; D Alex Quistberg; Anwar Rafay; Kazem Rahimi; Sajjad U Rahman; Murugesan Raju; Saleem M Rana; Homie Razavi; K Srinath Reddy; Amany Refaat; Giuseppe Remuzzi; Serge Resnikoff; Antonio L Ribeiro; Lee Richardson; Jan Hendrik Richardus; D Allen Roberts; David Rojas-Rueda; Luca Ronfani; Gregory A Roth; Dietrich Rothenbacher; David H Rothstein; Jane T Rowley; Nobhojit Roy; George M Ruhago; Mohammad Y Saeedi; Sukanta Saha; Mohammad Ali Sahraian; Uchechukwu K A Sampson; Juan R Sanabria; Logan Sandar; Itamar S Santos; Maheswar Satpathy; Monika Sawhney; Peter Scarborough; Ione J Schneider; Ben Schöttker; Austin E Schumacher; David C Schwebel; James G Scott; Soraya Seedat; Sadaf G Sepanlou; Peter T Serina; Edson E Servan-Mori; Katya A Shackelford; Amira Shaheen; Saeid Shahraz; Teresa Shamah Levy; Siyi Shangguan; Jun She; Sara Sheikhbahaei; Peilin Shi; Kenji Shibuya; Yukito Shinohara; Rahman Shiri; Kawkab Shishani; Ivy Shiue; Mark G Shrime; Inga D Sigfusdottir; Donald H Silberberg; Edgar P Simard; Shireen Sindi; Abhishek Singh; Jasvinder A Singh; Lavanya Singh; Vegard Skirbekk; Erica Leigh Slepak; Karen Sliwa; Samir Soneji; Kjetil Søreide; Sergey Soshnikov; Luciano A Sposato; Chandrashekhar T Sreeramareddy; Jeffrey D Stanaway; Vasiliki Stathopoulou; Dan J Stein; Murray B Stein; Caitlyn Steiner; Timothy J Steiner; Antony Stevens; Andrea Stewart; Lars J Stovner; Konstantinos Stroumpoulis; Bruno F Sunguya; Soumya Swaminathan; Mamta Swaroop; Bryan L Sykes; Karen M Tabb; Ken Takahashi; Nikhil Tandon; David Tanne; Marcel Tanner; Mohammad Tavakkoli; Hugh R Taylor; Braden J Te Ao; Fabrizio Tediosi; Awoke M Temesgen; Tara Templin; Margreet Ten Have; Eric Y Tenkorang; Abdullah S Terkawi; Blake Thomson; Andrew L Thorne-Lyman; Amanda G Thrift; George D Thurston; Taavi Tillmann; Marcello Tonelli; Fotis Topouzis; Hideaki Toyoshima; Jefferson Traebert; Bach X Tran; Matias Trillini; Thomas Truelsen; Miltiadis Tsilimbaris; Emin M Tuzcu; Uche S Uchendu; Kingsley N Ukwaja; Eduardo A Undurraga; Selen B Uzun; Wim H Van Brakel; Steven Van De Vijver; Coen H van Gool; Jim Van Os; Tommi J Vasankari; N Venketasubramanian; Francesco S Violante; Vasiliy V Vlassov; Stein Emil Vollset; Gregory R Wagner; Joseph Wagner; Stephen G Waller; Xia Wan; Haidong Wang; Jianli Wang; Linhong Wang; Tati S Warouw; Scott Weichenthal; Elisabete Weiderpass; Robert G Weintraub; Wang Wenzhi; Andrea Werdecker; Ronny Westerman; Harvey A Whiteford; James D Wilkinson; Thomas N Williams; Charles D Wolfe; Timothy M Wolock; Anthony D Woolf; Sarah Wulf; Brittany Wurtz; Gelin Xu; Lijing L Yan; Yuichiro Yano; Pengpeng Ye; Gökalp K Yentür; Paul Yip; Naohiro Yonemoto; Seok-Jun Yoon; Mustafa Z Younis; Chuanhua Yu; Maysaa E Zaki; Yong Zhao; Yingfeng Zheng; David Zonies; Xiaonong Zou; Joshua A Salomon; Alan D Lopez; Theo Vos
Journal:  Lancet       Date:  2015-08-28       Impact factor: 79.321

10.  Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012-2013.

Authors:  Sarah H Landis; Hana Muellerova; David M Mannino; Ana M Menezes; MeiLan K Han; Thys van der Molen; Masakazu Ichinose; Zaurbek Aisanov; Yeon-Mok Oh; Kourtney J Davis
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-06-06
View more
  3 in total

1.  The role of retinoid-related orphan receptor-α in cigarette smoke-induced autophagic response.

Authors:  Hak-Su Kim; Chang Hyeok An; Danielle Teller; Su-Jin Moon; Gi Won Hwang; Jin Woo Song
Journal:  Respir Res       Date:  2022-05-04

Review 2.  High-Density Lipoproteins: A Role in Inflammation in COPD.

Authors:  Stanislav Kotlyarov
Journal:  Int J Mol Sci       Date:  2022-07-23       Impact factor: 6.208

3.  Global trends in smoking cessation research from 2002 to 2021: A bibliometric and visual analysis.

Authors:  Yingxin Xu; Zhengmin Gu; Ye Zhang; Miao He; Ben S Gerber; Rajani S Sadasivam; Feifan Liu; Zhongqing Wang
Journal:  Prev Med Rep       Date:  2022-09-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.